Latest Manufacturing Expansion News

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

DroneShield Limited has reported a stellar 277% revenue surge in FY2025, underpinned by a booming SaaS segment and a robust $2.09 billion sales pipeline. The company is scaling manufacturing and capitalising on new US legislation to expand its counter-drone technology footprint.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Anteris Technologies has launched a $200 million public offering alongside a $90 million strategic investment from Medtronic, aiming to accelerate its DurAVR heart valve clinical trials and manufacturing expansion.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Electro Optic Systems (EOS) has landed a US$22 million deal to supply Remote Weapon Systems for a major U.S. Army combat vehicle, marking a significant milestone in its U.S. market expansion. This contract boosts EOS’s contract backlog to over A$400 million, setting the stage for robust revenue growth in the coming years.

Electro Optic Systems has inked a conditional US$80 million contract to supply a 100kW high energy laser weapon to a South Korean customer, marking its second major export order in this advanced defence technology.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.